Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.

EMA Issues Call for Expressions of Interest for Drug Safety Studies

The purpose of this call is to enable the EMA to obtain fast and reliable answers to questions on safety or benefit/risk concerns, and ultimately facilitating regulatory decision-making.

EHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials

EHA has responded to the EMA’s call for comments on the reflection paper on February 15.

Report "Haematology and the next European Decade"

EHA and the European Cancer Patient Coalition co-hosted a meeting at the European Parliament in Brussels on August 30-31, 2011. The two-day conference was attended by doctors, researchers, parliamentarians, patient advocates and Commission officials.

Horizon 2020: The European Commission proposes the successor to Framework Programme 7

Horizons 2020 will pay “particular attention to ensuring a broad approach to innovation, which is not only limited to the development of new products and services on the basis of scientific and technological breakthroughs, but which also incorporates aspects such…

5th Focus in Paediatric Haematology-Oncology

The course, which is particularly aimed at specialist trainees in pediatric haemato-oncology, continued the same ethos which inspired the first four courses: the importance of close interactions between the participants and the teaching faculty, a strong emphasis on real cases…

Brussels Declaration on the Recognition of Professional QualificationsThe future of the Harmonisation of the Haematology Curriculum in Europe

On the occasion of the meeting, there was unanimous support for the

“Brussels Declaration on the Recognition of Professional Qualifications” that follows:

The mobility of haematology trainees is of the utmost importance.

New at EHA 15: EHA-JSH Joint Symposium

On behalf of JSH Dr Toshiki Watanabe will speak about "Molecular pathogenesis of ATL". Dr Herman Einsele presents EHA with his lecture "New treatments strategies for EBV-associated LPD as a model for immunotherapy of virus-associated/induced tumors".

EHA Meetings

Application forms redirect